[Comparative study of maintenance of patency of triple lumen central venous catheter]. / Estudio comparativo del mantenimiento de la permeabilidad de los catéteres venosos centrales de tres luces.

OBJECTIVE: Establish an action protocol for the maintenance of patency of the three lumen central venous catheters (CVC) when any of them are not used. The main variable of interest was evaluate it 24 hours. MATERIAL AND METHOD: This is a blind, randomized clinical trial. Phase 1: Comparison of efficacy, for maintenance of patency of the lumen at 24 hours and on discharge of the patient, of sodium heparin 500 IU (control 1), versus sodium heparin 100 IU (study 1). Phase 2: Once efficacy of sodium heparin 100 IU (control 2) was confirmed, we compared it with saline solution (SS) (study 2). POPULATION: multiple diseased patients admitted to eight critical care unit who were carriers of 3 lumen CVC without previous coagulation disorders. ANALYSIS: quantitative variables with mean (SD) analyzed with Student's t test and qualitative ones with -2. ANALYSIS: SPSS 12.0 program. RESULTS: Phase 1: 128 catheters (control 1: 49, study 1: 79). Mean days of permanency with CVC: 5.4 (SD 6). At 24h, 100% of the CVC of both groups were patent. On discharge of the patient (n = 107) were not patent and 4.9% of the control group and 4.5% of the study group 1. Phase 2: 95 catheters (control 2: 38, study 2: 57) Mean days of permanency: 4.87 (SD 5). At 24h (n = 95), at 72 h (n = 66) and on discharge (n = 43), 100% of the CVC of both groups were patent. No significant difference was established in the two study phases between the groups studied with days of permanence, laboratory values and anticoagulant treatment. CONCLUSIONS: SS is as effective as 100 or 500 IU of heparin for maintenance of patency of CVC.

Estudio comparativo del mantenimiento de la permeabilidad de los catéteres venosos centrales de tres luces / Comparative study of maintenance of patency of triple lumen central venous catheter

Objetivo. Establecer un protocolo de actuación para el mantenimiento de la permeabilidad de los catéteres venosos centrales (CVC) de tres luces cuando alguna de ellas no se utilice. La variable principal de interés se evaluó a las 24 horas. Material y método. Se trata de un ensayo clínico ciego aleatorizado. Fase1: Comparación de la eficacia para el mantenimiento de la permeabilidad de la luz a las 24 horas y al alta del paciente, de la heparina sódica 500 UI (control 1), frente a la heparina sódica 100 UI (estudio 1). Fase 2: una vez confirmada la eficacia de la heparina sódica 100 UI (control 2) la comparamos con suero salino fisiológico (SF) (estudio 2). Población: enfermos pluripatológicos ingresados en una unidad de cuidados críticos portadores de CVC de tres luces sin trastornos de coagulación previos. Análisis: variables cuantitativas con media (desviación estándar [DE]) analizadas con la «t» de Student y las cualitativas con Chi2. Análisis: programa SPSS 12.0©. Resultados. Fase 1: 128 catéteres (control 1: 49; estudio 1: 79). La media de días de permanencia de los CVC: 5,4 (DE 6). A las 24 horas el 100% de los CVC de ambos grupos eran permeables. Al alta del paciente (n = 107) fueron no permeables el 4,9% grupo control 1 y el 4,5% grupo estudio 1. Fase 2: 95 catéteres (control 2: 38; estudio 2: 57) La media de días de permanencia: 4,87 (DE 5) a las 24 horas (n = 95), a las 72 horas (n = 66) y al alta (n = 43); el 100% de los CVC de ambos grupos eran permeables. No se estableció ninguna diferencia significativa en las dos fases del estudio entre los grupos estudiados con los días de permanencia, valores analíticos y tratamiento anticoagulante. Conclusiones. El SF es igualmente eficaz que 100 o 500 UI de heparina para el mantenimiento de la permeabilidad de los CVC

Objective. Establish an action protocol for the maintenance of patency of the three lumen central venous catheters (CVC) when any of them are not used. The main variable of interest was evaluate it 24 hours. Material and methods. This is a blind, randomized clinical trial. Phase 1: Comparison of efficacy, for maintenance of patency of the lumen at 24 hours and on discharge of the patient, of sodium heparin 500 IU (control 1), versus sodium heparin 100 IU (study 1). Phase 2: Once efficacy of sodium heparin 100 IU (control 2) was confirmed, we compared it with saline solution (SS) (study 2). Population: multiple diseased patients admitted to eight critical care unit who were carriers of 3 lumen CVC without previous coagulation disorders. Analysis: quantitative variables with mean (SD) analyzed with Student's t test and qualitative ones with ¯2. Analysis: SPSS 12.0 program®. Results. Phase 1: 128 catheters (control 1: 49, study 1: 79). Mean days of permanency with CVC: 5.4 (SD 6). At 24h, 100% of the CVC of both groups were patent. On discharge of the patient (n = 107) were not patent and 4.9% of the control group and 4.5% of the study group 1. Phase 2: 95 catheters (control 2: 38, study 2: 57) Mean days of permanency: 4.87 (SD 5). At 24h (n = 95), at 72h (n = 66) and on discharge (n = 43), 100% of the CVC of both groups were patent. No significant difference was established in the two study phases between the groups studied with days of permanence, laboratory values and anticoagulant treatment. Conclusions. SS is as effective as 100 or 500 IU of heparin for maintenance of patency of CVC